Use of the 22C3 anti–PD-L1 antibody to determine PD-L1 expression in multiple automated immunohistochemistry platforms

BACKGROUND: For non–small cell lung cancer (NSCLC), treatment with pembrolizumab is limited to patients with tumours expressing PD-L1 assessed by immunohistochemistry (IHC) using the PD-L1 IHC 22C3 pharmDx (Dako, Inc.) companion diagnostic test, on the Dako Autostainer Link 48 (ASL48) platform. Opti...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:PLoS One
Päätekijät: Ilie, Marius, Khambata-Ford, Shirin, Copie-Bergman, Christiane, Huang, Lingkang, Juco, Jonathan, Hofman, Veronique, Hofman, Paul
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Public Library of Science 2017
Aiheet:
Research Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC5552229/
https://ncbi.nlm.nih.gov/pubmed/28797130
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0183023
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia